Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma

Asian Journal of Andrology

Volumn 13, Issue 2, 2011, Pages 242-247

  Mazzucchelli, Roberta ^a   Morichetti, Doriana ^a   Scarpelli, Marina ^a   Bono, Aldo V ^a   Lopez Beltran, Antonio ^b   Cheng, Liang ^c   Kirkali, Ziya ^d   Montironi, Rodolfo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

hormone refractory prostate cancer; prostate cancer progression; prostatic adenocarcinoma; somatostatin receptors

Indexed keywords

RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; MALE; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMOOTH MUSCLE FIBER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; SUBCELLULAR FRACTIONS;

EID: 79952414787     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.100     Document Type: Article

References (30)

1. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 1999; 59: 1947-53. (Pubitemid 29186170)
2. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostatecancer. Cancer 1993; 71: 1098-109. (Pubitemid 23049638)
3. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998; 160: 1220-9. (Pubitemid 29480485)
4. Sivam GP, Martin PJ, Reisfeld RA, Mueller BM. Therapeutic efficacyof adoxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res 1995; 55: 2352-6.
5. Yeh MY, Roffler SR, Yu MH. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma. Int J Cancer 1992; 51: 274-82.
6. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004; 15: 300-10. (Pubitemid 39193184)
7. Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V et al. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancercell lines. Urol Oncol 2002; 7: 91-8.
8. Mazzucchelli R, Morichetti D, Santinelli A, Scarpelli M, Bono AV et al. Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer following complete androgen ablation. Anal Cell Pathol (Amst) 2010; 33: 27-36; doi: 10.3233/CLO-2008-0433.
9. Morichetti D, Mazzucchelli R, Santinelli A, Stramazzotti D, Lopez-Beltran A et al. Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. Int J Immunopathol Pharmacol 2010; 23: 511-22.
10. Morichetti D, Mazzucchelli R, Stramazzotti D, Santinelli A, Lopez-Beltran A etal. Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. BJU Int; e-pub ahead of print 1 May 2010; 106: 1072-80.
11. Montironi R, Cheng L, Mazzucchelli R, Morichetti D, Stramazzotti D et al. Immunohistochemical detection and localization of somatostatin receptor subtypes in prostatetissuefrom patients with bladder outlet obstruction. Cell Oncol 2008; 30: 473-82.
12. Brazeau P, Vale W, Burgus R, Ling N, Butcher M etal. Hypothalamic polypeptidethat inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.
13. Bousquet C, Guillermet J, Vernejoul F, Lahlou H, Buscail L et al. Somatostatin receptorsand regulation of cell proliferation. Dig Liver Dis 2004; 36 Suppl 1: S2-7. (Pubitemid 41115483)
14. 2 in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol 2001; 280: 457-65.
15. Casini Raggi C, CalabròA, Renzi D, Briganti V, Cianchi F etal. Quantitativeevaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and inthe corresponding normal mucosa. Clin Cancer Res 2002; 8: 419-27. (Pubitemid 34193959)
16. Portela-Gomes MG, Stridsberg M, Grimelius L, Oberg K,Janson ET. Expressionof the fivedifferentsomatostatin receptor subtypes in endocrinecellsof the pancreas. Appl Immunohistochem Mol Morphol 2002; 8: 126-32. (Pubitemid 30609973)
17. Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U etal. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004; 53: 1180-9. (Pubitemid 38961975)
18. Zatelli MC, degli Uberti EC Somatostatin receptors: from basic scienceto clinical approach\thyroid. Dig Liver Dis 2004; 36: 86-92.
19. Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson PA. Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 2002; 53: 50-9. (Pubitemid 34966863)
20. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995; 80: 2806-14.
21. Verset G, Verslype C, Reynaert H, Borbath I, Langlet P et al. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer 2007; 97: 582-8. (Pubitemid 47339881)
22. Cariaga-Martinez AE, Lorenzati MA, Riera MA,Cubilla MA, dela Rossa Aetal.Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression. Adv Urol; e-pub ahead of print 12 April 2009; doi: 10.1155/2009/723831.
23. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG et al. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000; 85: 2564-71. (Pubitemid 32269216)
24. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I etal. Somatostatin receptortype 2A immunohistochemistry in neuroendocrine tumors: a proposal of a scoring system correlatedwithsomatostatin receptorscintigraphy. Mod Pathol 2007; 20: 1172-82. (Pubitemid 47609066)
25. Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238. J Urol 2004; 171: 911-5. (Pubitemid 38090532)
26. 1]-octreotidescintigraphy. Cancer Res 1995; 55: 5805s-10s.
27. Mencoboni M, Tredici S, Rebella L, Bergaglio M, Galbusera V et al. Effect of chemotherapy on somatostatin receptor detection with octreotide scintigraphy in hormone-refractory prostate cancer patients. Anticancer Res 2006; 26: 2233-5. (Pubitemid 43980178)
28. Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski Aetal. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostatecancer in ratsat nontoxicdoses. Cancer Res 1998; 58: 4132-7. (Pubitemid 28440570)
29. Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T etal. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opin Investig Drugs 2006; 15: 795-804.
30. Klisovic DD, O'Dorisio MS, Katz SE, Sall JW, Balster Detal. Somatostatinreceptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest Ophthalmol Vis Sci 2001; 42: 2193-201. (Pubitemid 32848846)